Raykova, Doroteya http://orcid.org/0000-0001-6452-2199
Kermpatsou, Despoina http://orcid.org/0000-0001-5872-4472
Malmqvist, Tony http://orcid.org/0000-0003-0609-2009
Harrison, Philip J.
Sander, Marie Rubin http://orcid.org/0000-0002-9783-5682
Stiller, Christiane http://orcid.org/0000-0002-6552-8426
Heldin, Johan http://orcid.org/0000-0002-0915-5303
Leino, Mattias
Ricardo, Sara http://orcid.org/0000-0003-4091-2226
Klemm, Anna http://orcid.org/0000-0002-3466-1320
David, Leonor http://orcid.org/0000-0003-4207-9258
Spjuth, Ola http://orcid.org/0000-0002-8083-2864
Vemuri, Kalyani http://orcid.org/0000-0003-2544-5412
Dimberg, Anna http://orcid.org/0000-0003-4422-9125
Sundqvist, Anders
Norlin, Maria http://orcid.org/0000-0003-4348-6269
Klaesson, Axel
Kampf, Caroline
Söderberg, Ola http://orcid.org/0000-0003-2883-1925
Funding for this research was provided by:
Vetenskapsrådet
Cancerfonden
Stiftelsen för Strategisk Forskning
Article History
Received: 1 July 2021
Accepted: 29 July 2022
First Online: 13 August 2022
Change Date: 6 September 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-41325-3
Competing interests
: The authors declare the following competing interests: O. Söderberg is the inventor of the MolBoolean method, with patent number: US2022042069A1-2022-02-10. The patent is now held by Atlas Antibodies, therefore, as employees of Atlas Antibodies, T.M. and C.K. declare financial interest. The remaining authors declare no competing interests.